non-viral gene delivery

Genetic Medicines Inspired by Nature Revolutionizing Gene Therapy With Non-Viral Delivery Methods for Stargardt's, ALS, Alzheimer’s, Duchenne & other Systemic Diseases Learn How It Works Pioneering Non-Viral Gene Delivery At AAVINUE, we are driven by a vision to revolutionize gene therapy for debilitating diseases using our proprietary Mini-nucleosome non-viral delivery technology. Our work is dedicated to overcoming the challenges of viral vectors and LNPs to enable transformative therapies for conditions like ALS, Stargardt's, Alzheimer’s Disease, and other genetic diseases. Patient Focused Patient first mentality drives our entire drug development process. Cutting-Edge Technology Leader in non-viral gene Delivery and Cargo technologies. Robust Platforms Customizable for targeted delivery of DNA/RNA to treat diverse diseases Designed for Success Highly accessible to patients via.

Read more

gene therapy developmenttargeted delivery of DNA/RNA

DNA Nanobots, Inc. is a preclinical-stage platform technology company founded in 2021 in Columbus, Ohio, as a spin-out from The Ohio State University. It develops Genobots, non-viral delivery systems in which gene-bearing DNA is folded into a defined nanoscale structure carrying targeting and trafficking elements, building on over a decade of DNA-origami research. The architecture is being evaluated across genetic diseases including Duchenne muscular dystrophy; no program has been designated a lead and there are no approved products.

Read more

DNA origamipreclinical developmentself-assembly